AGILENT TECHNOLOGIES INC (NYSE:A) reported financial results for its first quarter of fiscal year 2026, delivering a performance that was largely in line with analyst expectations on profitability but fell short on the top line. The market's immediate reaction was negative, with shares trading down approximately 3% in after-hours activity following the announcement.
Quarterly Results Versus Expectations
The life sciences tools company reported revenue of $1.80 billion for the quarter ended January 31, 2026, representing a 7.0% increase year-over-year on a reported basis. However, this figure came in below the analyst consensus estimate of $1.84 billion. On the bottom line, the company's non-GAAP earnings per share (EPS) of $1.36 matched the Wall Street estimate of $1.36.
The key financial metrics compared to expectations are as follows:
- Reported Revenue: $1.80 billion
- Analyst Estimate: $1.84 billion
- Variance: Missed by approximately 2.4%
- Non-GAAP EPS: $1.36
- Analyst Estimate: $1.36
- Variance: In line
On a GAAP basis, net income was $305 million, or $1.07 per share, compared to $318 million, or $1.11 per share, in the prior-year period. The company attributed part of the quarter's performance to a major U.S. snowstorm during the final week, which impacted operations. CEO Padraig McDonnell stated that on a normalized basis, excluding this weather impact, results would have exceeded the midpoint of the company's guidance.
Market Reaction and Segment Performance
The negative after-hours price action suggests investor disappointment centered on the revenue miss, despite the earnings beat. The stock had been relatively stable in the weeks leading up to the report, with a slight decline of about 0.6% over the past month.
The press release detailed growth across all three of Agilent's business segments on both a reported and core basis (which excludes currency and M&A impacts):
- Agilent CrossLab Group (ACG): Revenue of $758 million, up 9% reported (6% core). This services and consumables segment was the top performer and maintained a high operating margin of 31.6%.
- Life Sciences and Diagnostics Markets Group (LDG): Revenue of $679 million, up 5% reported (3% core), with an operating margin of 16.0%.
- Applied Markets Group (AMG): Revenue of $361 million, up 7% reported (4% core), with an operating margin of 25.8%.
Forward Guidance and Analyst Estimates
Management provided an outlook for both the upcoming second quarter and the full 2026 fiscal year. This forward guidance offers a mixed picture when held against current analyst expectations.
For Q2 FY2026:
- Agilent's Revenue Outlook: $1.79 billion to $1.82 billion (approx. 7-9% reported growth).
- Analyst Sales Estimate: $1.80 billion.
- Agilent's Non-GAAP EPS Outlook: $1.39 to $1.42.
- Analyst EPS Estimate: $1.42.
For Full-Year FY2026:
- Agilent's Revenue Outlook: $7.3 billion to $7.5 billion.
- Analyst Sales Estimate: $7.51 billion.
- Agilent's Non-GAAP EPS Outlook: $5.90 to $6.04.
- Analyst EPS Estimate: $6.05.
The company's revenue guidance for the full year brackets the current analyst consensus but sets a high-end target slightly below it. Similarly, the high end of its EPS guidance range is just below the consensus estimate. Management noted it was modestly increasing its non-GAAP EPS range for the full year due to favorable currency impacts.
Conclusion
Agilent Technologies delivered a quarter of solid core growth but failed to meet revenue expectations, leading to a negative market reaction. While profitability met targets and all business segments expanded, the top-line miss and a forward outlook that appears cautious relative to analyst forecasts for the full year are likely weighing on investor sentiment. The company maintains its confidence in its instrument-replacement cycle and enterprise services, but the market will be looking for revenue acceleration to meet the higher end of its updated guidance.
For a detailed look at upcoming earnings dates and a complete history of analyst estimates for Agilent Technologies, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.